







an Open Access Journal by MDPI

Mechanisms of mRNA Translation in Pancreatic Cancer

Guest Editor:

Dr. Kamini Singh

Department of Molecular Pharmacology, Albert Einstein College of Medicine, Albert Einstein Cancer Center, Bronx, NY 10461, USA

Deadline for manuscript submissions:

15 December 2024

Message from the Guest Editor

Dear Colleagues,

We are seeking original research articles that explore the mechanistic aspects of mRNA translation control and its impact on the development and progression of pancreatic cancer. Specifically, we encourage studies that investigate the role of aberrant translation regulation in oncogenesis and the overexpression of oncogenic proteins in pancreatic cancer cells. We also welcome studies that elucidate the signaling pathways and molecular mechanisms involved in mRNA translation regulation and the effects of changes in the tumor microenvironment on translation in pancreatic cancer. Additionally, we are interested in studies that focus on developing novel therapeutic strategies for pancreatic cancer by targeting the translation machinery, such as inhibiting the activity of translation initiation factors or targeting specific mRNAs overexpressed in pancreatic cancer cells. The scope of this Special Issue is broadly on the mechanisms of mRNA translation in pancreatic cancer, and it involves a range of disciplines and techniques, including molecular biology, biochemistry, cancer cell biology, and therapeutics.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us